1.1Methylsulfonyl group at X1
An amine attacks the heteroaromatic carbon bonded to the sulfur atom. Methanesulfinate departs, and proton transfer gives the heteroaryl amine.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An amine attacks the heteroaromatic carbon bonded to the sulfur atom. Methanesulfinate departs, and proton transfer gives the heteroaryl amine.
Each of the four positions terminates in a carbon–hydrogen bond. In the chroman series, the C4 amino group still supplies the nitrogen for attachment to an activated pyrrolopyrimidine.
A palladium catalyst inserts into the bond between the aromatic carbon and the triflate oxygen. An amine binds, a base removes a proton from the bound amine, and reductive elimination forms the carbon–nitrogen bond.
The methoxycarbonyl group retains a carbonyl oxygen that accepts hydrogen bonds. Hydroxide hydrolyzes the methyl ester to a carboxylate, which gives the carboxylic acid upon acidification.
Sulfur forms two single bonds to the adjacent ring carbons, giving a cyclic thioether. The single-atom link preserves the ring atom count, while the longer carbon–sulfur bonds change the local ring geometry.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An analytical training laboratory uses a purified 3-substituted chroman–pyrrolopyrimidine amine and its corresponding heteroaryl coupling precursor as reference samples. The laboratory prepares individual solutions and a mixed sample in the same solvent. Trainees separate the mixture by liquid chromatography and assign each peak by matching its retention time and mass spectrum to the individual references.
A methylsulfonyl group replaces the halogen at C4 of the pyrrolopyrimidine coupling precursor. The precursor is heated with a 3-substituted chroman-4-amine and a tertiary amine base in a polar aprotic solvent. The chroman amine displaces methanesulfinate at C4 to form the exocyclic carbon–nitrogen bond.
A vial array holds 0.050 mmol of a halopyrrolopyrimidine coupling precursor and 0.060 mmol of a 3-substituted chroman-4-amine per vial. A tertiary amine base is held at 0.10 mmol per vial, and a polar aprotic solvent sets the precursor concentration to either 0.05 M or 0.20 M. Replicate vials are held at 75 °C and sampled after 30 and 120 minutes. Liquid chromatography measures precursor consumption and product formation at each concentration and time.
Two metering pumps feed separate solutions of the halopyrrolopyrimidine precursor and the chroman-4-amine with base into a static mixer. The mixed stream passes through a heated tubular reactor, and a back-pressure regulator maintains pressure above the solvent vapor pressure at the operating temperature. A sampling valve downstream of the regulator directs a diluted aliquot to a liquid chromatograph while the main stream flows into a cooled collection vessel.
A preparative supercritical fluid chromatography system separates stereoisomers of a 3-substituted chroman–pyrrolopyrimidine amine from a purified product mixture. The column contains a chiral polysaccharide stationary phase, and the mobile phase mixes compressed carbon dioxide with methanol containing a low concentration of a volatile amine modifier. An ultraviolet detector triggers collection of the resolved peaks into separate vessels. Analytical chiral chromatography measures the stereoisomer ratio in each collected fraction.
A liquid handler dispenses the coupling partners, solvents, and bases into sealed reaction vials and records the reagent amounts and heating settings for each position. After heating, it dilutes each sample for liquid chromatography with ultraviolet and mass detection. Software uses the expected mass to locate the product peak and calculates its ultraviolet peak area relative to an internal standard. A regression model uses those responses to select solvent, base loading, temperature, and time for the next batch.
R1a is cyano, and R1b, R1c, and R1d are hydrogen. The ring bonds directly to the nitrile carbon, and the linear carbon–nitrogen triple bond projects from that ring position.
R2 is —C(O)CH3, with methyl as the one-carbon alkyl group. The substituent attaches through the carbonyl carbon, and the carbonyl oxygen acts as a hydrogen-bond acceptor.
Bromine occupies the X2 position as a covalently attached halogen. At an aromatic carbon, the carbon–bromine bond serves as a coupling site for palladium-catalyzed bond formation.
Z is —O—, with one single bond to each adjacent ring carbon. The resulting cyclic ether contains an oxygen atom that accepts hydrogen bonds.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Compounds are represented in generic form, wherein X is a halogen and with substituents as noted in compound descriptions elsewhere herein.B · US 2020/0399264 A1 · ¶ 269
R1=halogen, methyl, C1-C4-haloalkyl, methoxy, methylthio, methylsulfinyl or methylsulfonyl;A · US 2008/0171774 A1 · abstract
wherein each of R31a, R31b, R31c, and R31d is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, C1-C4 aminoalkyl, —C(O)R11, —CO2R12, —C(O)NR13, and —SO2R14; wherein R32 is selected from —CN and —CH2NH2; and wherein Ar2 is selected from 5-membered heterocycle, 6-membered heterocycle, 5-membered heteB · US 2020/0399264 A1 · ¶
Suitable monovalent substituents on R∘ (or the ring formed by taking two independent occurrences of R∘ together with their intervening atoms), are independently halogen, —(CH2)0-2R●, -(haloR●), —(CH2)0-2OH, —(CH2)0-2OR*, —(CH2)0-2CH(OR●)2; —O(haloR●), —CN, —N3, —(CH2)0-2C(O)R●, —(CH2)0-2C(O)OH, —(CH2)0-2C(O)OR●, —(CH2)0-2SR●, —(CH2)0-2SH, —(CH2)0-2NH2, —(CH2)0-2NHR●, —(CH2)0-2NR●2, —NO2, —SiR●3, —OSiR●3, —C(O)SR●, —(C1-4 straight or branched alkylene)C(O)OR●, or —SSR● whereinB · US 2020/0399264 A1 · ¶ 81
Particular preference is given to compounds I having the following combinations of substituents, where the substituents are as defined below: X2 is F or chlorine;A · US 2008/0171774 A1 · ¶ 61
An empty cell means only that no passage was reproduced there.
It was an object of the present invention to provide nicotinanilides whose fungicidal action is better than that of the compounds of the prior art.A · US 2008/0171774 A1 · ¶ 15
We have found that this object is achieved by the compounds I defined at the outset.A · US 2008/0171774 A1 · ¶ 16
Despite the widespread distribution and severity of the effects of these viral infections, a treatment for ZIKV, DENV, VEEV, EEEV, WEEV and CHIKV has remained elusive.B · US 2020/0399264 A1 · ¶ 7
Thus, there remains a need for antiviral agents capable of targeting these viruses and methods of making and using same.B · US 2020/0399264 A1 · ¶ 7
patent.fyi, US 2026/0356839 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356839/, SHA-256 c988af4e9113577e7c82a430adb40715ad35bb848e6aa189196e88ff3e856310